Key clinical point: The EPclin assay is predictive of absolute chemotherapy benefit in ER+/HER2– breast cancer.
Major finding: The absolute 10-year benefit for patients with high scores would be 5.3 to 7.3%.
Study details: Description of a mathematical model to predict absolute chemotherapy benefit in women with estrogen receptor–positive, HER2-negative breast cancer.
Disclosures: The study was supported by Myriad Genetics. Dr. Gradishar disclosed consulting or advisory roles with Genentech and Roche. Five of the coauthors are employees of Myriad Genetics or Myriad International.
Gradishar W et al. Precision Oncology. 2016 Aug. 6. doi: 10.1200/PO.18.00361.